phospho-IKB alpha (Ser36)抗体特异性结合抗原：抗体本身不能直接溶解或杀伤带有特异抗原的靶细胞，通常需要补体或吞噬细胞等共同发挥效应以**病原微生物或导致病理损伤。然而，抗体可通过与病毒或**的特异性结合，直接发挥中和病毒的作用。
产物编号xy- 18129R
英文名称phospho-IKB alpha (Ser36)
中文名称磷酸化核因子κ叠抑制蛋白α抗体体
别 名IKB alpha (phospho S36); p-IKB alpha (phospho S36); I kappa B alpha; I-kappa-B-alpha; IkappaBalpha; IkB-alpha; IKBA; IKBA_HUMAN; IKBalpha; MAD 3; MAD3; Major histocompatibility complex enhancer-binding protein MAD3; NF kappa B inhibitor alpha; NF-kappa-B inhibitor alpha; NFKBI; NFKBIA; Nuclear factor of kappa light chain gene enhancer in B cells; Nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor alpha.
说 明 书100ul
产物类型磷酸化抗体
研究领域肿瘤 细胞生物 神经生物学 信号转导 细胞凋亡 激酶和磷酸酶
抗体来源搁补产产颈迟
克隆类型笔辞濒测肠濒辞苍补濒
phospho-IKB alpha (Ser36)抗体交叉反应 Human, Mouse, Rat, Pig, Cow, Rabbit, Sheep,
产物应用WB=1:500-2000 ELISA=1:500-1000 IHC-P=1:400-800 IHC-F=1:400-800 ICC=1:100-500 IF=1:100-500 （石蜡切片需做抗原修复）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量35kDa
细胞定位细胞核 细胞浆
性 状Lyophilized or Liquid
浓 度1mg/1ml
免 疫 原KLH conjugated Synthesised phosphopeptide derived from human IKB alpha around the phosphorylation site of Ser36:LD(p-S)MK
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
phospho-IKB alpha (Ser36)抗体保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
PubMedPubMed
产物介绍产补肠办驳谤辞耻苍诲:
This gene encodes a member of the NF-kappa-B inhibitor family, which contain multiple ankrin repeat domains. The encoded protein interacts with REL dimers to inhibit NF-kappa-B/REL complexes which are involved in inflammatory responses. The encoded protein moves between the cytoplasm and the nucleus via a nuclear localization signal and CRM1-mediated nuclear export. Mutations in this gene have been found in ectodermal dysplasia anhidrotic with T-cell immunodeficiency autosomal dominant disease. [provided by RefSeq, Aug 2011]
Function:
Inhibits the activity of dimeric NF-kappa-B/REL complexes by trapping REL dimers in the cytoplasm through masking of their nuclear localization signals. On cellular stimulation by immune and proinflammatory responses, becomes phosphorylated promoting ubiquitination and degradation, enabling the dimeric RELA to translocate to the nucleus and activate transcription.
Subcellular Location:
Cytoplasm. Nucleus. Shuttles between the nucleus and the cytoplasm by a nuclear localization signal (NLS) and a CRM1-dependent nuclear export.
Post-translational modifications:
Phosphorylated; disables inhibition of NF-kappa-B DNA-binding activity. Phosphorylation at positions 32 and 36 is prerequisite to recognition by UBE2D3 leading to polyubiquitination and subsequent degradation. Sumoylated; sumoylation requires the presence of the nuclear import signal. Monoubiquitinated at Lys-21 and/or Lys-22 by UBE2D3. Ubiquitin chain elongation is then performed by CDC34 in cooperation with the SCF(FBXW11) E3 ligase complex, building ubiquitin chains from the UBE2D3-primed NFKBIA-linked ubiquitin. The resulting polyubiquitination leads to protein degradation. Also ubiquitinated by SCF(BTRC) following stimulus-dependent phosphorylation at Ser-32 and Ser-36.
Deubiquitinated by porcine reproductive and respiratory syndrome virus Nsp2 protein, which thereby interferes with NFKBIA degradation and impairs subsequent NF-kappa-B activation.
DISEASE:
Defects in NFKBIA are the cause of ectodermal dysplasia anhidrotic with T-cell immunodeficiency autosomal dominant (ADEDAID) [MIM:612132]. Ectodermal dysplasia defines a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. ADEDAID is an ectodermal dysplasia associated with decreased production of pro-inflammatory cytokines and certain interferons, rendering patients susceptible to infection.
Similarity:
Belongs to the NF-kappa-B inhibitor family.
Contains 5 ANK repeats.
SWISS:
P25963
Gene ID:
4792
phospho-IKB alpha (Ser36)抗体（antibody,
Ab）是由效应B细胞（效应**B细胞）分泌，机体用于抵御外来物质，如病毒，**等抗原，结构呈“驰”字型的球状蛋白质，仅仅存在于脊椎动物的血液和B**细胞膜表面。凡是能够跟抗体结合的物质，均被称作抗原，因此对于抗抗体（能够结合抗体的抗体）来说，抗体本身也是一种抗原物质。
phospho-IKB alpha (Ser36)抗体普通抗体重链和轻链的结构
重链结构：普通的**球蛋白具有2条重链（H链），分子量约为50kD,有μ、δ、γ、ε和α五种重链亚型，对应的**球蛋白名称分别为IgM、IgG、IgA、IgD和IgE。
轻链结构： 普通**球蛋白具有2条轻链（L链），分子质量约25kDa，有κ链和λ链两种亚型，这两种轻链决定了Ig的亚型类别（IgG1，IgG2，IgG3，IgG4）。一个天然的Ig分子两条轻链总是相同的，但在同一个体内可存在分别带有κ或λ链的抗体分子。不同种属生物体内两型轻链的比例不同，正常人血清**球蛋白κ链：λ链约为2：1，而在小鼠的比例为20：1。
2.2抗体Fab段和Fc段
滨驳骋经木瓜蛋白酶酶切后裂解为2个完全相同的Fab段和1个Fc段,每个Fab段都为单价,可与抗原结合但不会再发生凝集反应；经胃蛋白酶酶切后裂解为1个完整F(ab)2片段和碎片化的Fc片段,F(ab’)2片段为双价,可同时结合两个抗原表位。Fab段为抗原结合片段（fragment of antigen binding，Fab），相当于抗体分子的两个臂，由一个完整的轻链和重链的VH和CH1结构域组成。Fc段为可结晶段（fragment crystallizable，Fc）相当于Ig的CH2和CH3结构域，是Ig与效应分子或者细胞相互作用的部位。Fab段包含完整的可变区，以及恒定区的CH1区域。Fc段仅指Ig恒定区CH2和CH3的区域，相当于Y字结构下面那一部分。
合格 ERCC1 DNA切除修复蛋白1抗体
合格 合格 SCARA3 细胞应激反应蛋白抗体
合格 SCARA5 清道夫受体A亚型5抗体
合格 SCARF2 清道夫受体F2抗体
合格 Scavenger Receptor BI + BII 清道夫受体B1+B2抗体
合格 SCD5 硬脂酰辅酶A去饱和酶5抗体
合格 SFRS4 丝氨酸/苏氨酸SRP75抗体
合格 SFRS8 丝氨酸/苏氨酸SFRS8抗体
合格 SFXN1 三羧酸载体蛋白SFXN1抗体
合格 SGCE SGCE蛋白抗体
合格 SGK196 SGK196蛋白抗体
合格 phospho-c-Raf(Ser338/Tyr340) 磷酸化原癌基因c-Raf抗体
合格 TEFF1 TEFF1蛋白抗体
合格 合格 LULL1/TOR1AIP2 LULL1蛋白抗体
合格 hnRNP H 异质核糖核蛋白H抗体
合格 hnRNP M3-M4 异质核糖核蛋白M3-M4抗体
合格 hnRNP DL 异质核核糖核蛋白D样蛋白抗体
合格 HNRPUL1 异质核核糖核蛋白U样蛋白1抗体
合格 E2F5 转录因子E2F-5抗体
合格 Homez 同源盒亮氨酸拉链蛋白HOMEZ抗体
合格 HOPX 绒毛膜癌不表达蛋白1抗体
合格 Host cell factor C2 宿主细胞因子2抗体
合格 TCL3/HOX11 T细胞白血病**瘤蛋白3抗体
合格 HOXA1 同源盒蛋白A1抗体
合格 HOXB1 同源盒蛋白HOXB1抗体
合格 HOXB9 同源盒蛋白B9抗体
合格 HOXD3 同源盒蛋白D3抗体
合格 HP1BP3 异染色质蛋白1结合蛋白3抗体
合格 HPS2 HPS2蛋白抗体
合格 HPS6 Hermansky-Pudlak综合征蛋白6抗体
合格 HS2ST1 HS2ST1蛋白抗体
合格 合格 phospho-c-kit(Tyr936) 磷酸化原癌基因c-kit抗体